JP2011520977A5 - - Google Patents

Download PDF

Info

Publication number
JP2011520977A5
JP2011520977A5 JP2011510691A JP2011510691A JP2011520977A5 JP 2011520977 A5 JP2011520977 A5 JP 2011520977A5 JP 2011510691 A JP2011510691 A JP 2011510691A JP 2011510691 A JP2011510691 A JP 2011510691A JP 2011520977 A5 JP2011520977 A5 JP 2011520977A5
Authority
JP
Japan
Prior art keywords
composition
pharmaceutically acceptable
solvate
compound
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011510691A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011520977A (ja
JP5757864B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/044743 external-priority patent/WO2009143295A1/en
Publication of JP2011520977A publication Critical patent/JP2011520977A/ja
Publication of JP2011520977A5 publication Critical patent/JP2011520977A5/ja
Application granted granted Critical
Publication of JP5757864B2 publication Critical patent/JP5757864B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011510691A 2008-05-20 2009-05-20 水溶性アセトアミノフェン類似体 Expired - Fee Related JP5757864B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5477408P 2008-05-20 2008-05-20
US61/054,774 2008-05-20
PCT/US2009/044743 WO2009143295A1 (en) 2008-05-20 2009-05-20 Water-soluble acetaminophen analogs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014049672A Division JP2014111658A (ja) 2008-05-20 2014-03-13 水溶性アセトアミノフェン類似体

Publications (3)

Publication Number Publication Date
JP2011520977A JP2011520977A (ja) 2011-07-21
JP2011520977A5 true JP2011520977A5 (enExample) 2012-07-05
JP5757864B2 JP5757864B2 (ja) 2015-08-05

Family

ID=41340538

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2011510691A Expired - Fee Related JP5757864B2 (ja) 2008-05-20 2009-05-20 水溶性アセトアミノフェン類似体
JP2014049672A Withdrawn JP2014111658A (ja) 2008-05-20 2014-03-13 水溶性アセトアミノフェン類似体
JP2016016971A Expired - Fee Related JP6063072B2 (ja) 2008-05-20 2016-02-01 水溶性アセトアミノフェン類似体
JP2016242968A Withdrawn JP2017057217A (ja) 2008-05-20 2016-12-15 水溶性アセトアミノフェン類似体
JP2018098716A Withdrawn JP2018135392A (ja) 2008-05-20 2018-05-23 水溶性アセトアミノフェン類似体
JP2020074690A Withdrawn JP2020114876A (ja) 2008-05-20 2020-04-20 水溶性アセトアミノフェン類似体

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2014049672A Withdrawn JP2014111658A (ja) 2008-05-20 2014-03-13 水溶性アセトアミノフェン類似体
JP2016016971A Expired - Fee Related JP6063072B2 (ja) 2008-05-20 2016-02-01 水溶性アセトアミノフェン類似体
JP2016242968A Withdrawn JP2017057217A (ja) 2008-05-20 2016-12-15 水溶性アセトアミノフェン類似体
JP2018098716A Withdrawn JP2018135392A (ja) 2008-05-20 2018-05-23 水溶性アセトアミノフェン類似体
JP2020074690A Withdrawn JP2020114876A (ja) 2008-05-20 2020-04-20 水溶性アセトアミノフェン類似体

Country Status (12)

Country Link
US (4) US20110212926A1 (enExample)
EP (1) EP2291348A4 (enExample)
JP (6) JP5757864B2 (enExample)
KR (1) KR101698028B1 (enExample)
CN (2) CN105254662A (enExample)
AU (1) AU2009249067A1 (enExample)
BR (1) BRPI0912326A2 (enExample)
CA (1) CA2724877C (enExample)
IL (1) IL209382A0 (enExample)
MX (1) MX2010012648A (enExample)
RU (1) RU2010151952A (enExample)
WO (1) WO2009143295A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010012648A (es) 2008-05-20 2010-12-14 Neurogesx Inc Analogos de acetaminofeno solubles en agua.
US20110263545A1 (en) 2008-05-20 2011-10-27 Naweed Muhammad Hepatoprotectant acetaminophen mutual prodrugs
JP5519645B2 (ja) 2008-05-20 2014-06-11 ニューロジェシックス， インコーポレイテッド カーボネートプロドラッグおよびそれを使用する方法
EP2177215A1 (en) 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and NSAIDs
WO2012137225A1 (en) * 2011-04-08 2012-10-11 Sphaera Pharma Pvt. Ltd Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds
US9024055B2 (en) 2011-09-22 2015-05-05 Acorda Therapeutics, Inc. Acetaminophen conjugates, compositions and methods of use thereof
CA2919892C (en) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
AU2015303835B2 (en) 2014-08-12 2020-04-09 Monash University Lymph directing prodrugs
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
JP6567049B2 (ja) 2014-10-21 2019-08-28 アッヴィ・インコーポレイテッド カルビドパおよびｌ−ドーパプロドラッグならびにそれらの使用方法
US10682337B2 (en) 2015-03-03 2020-06-16 Kindred Biosciences, Inc. Compositions and methods for treatment and prevention of pyrexia in horses
CA2997106C (en) 2015-09-08 2024-06-04 Monash University Lymph directing prodrugs
WO2017184871A1 (en) * 2016-04-20 2017-10-26 Abbvie Inc. Carbidopa and l-dopa prodrugs and methods of use
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
EP3675838A4 (en) 2017-08-29 2021-04-21 PureTech LYT, Inc. LIPID PRODRUGS DIRECTED TO THE LYMPHATIC SYSTEM
EP3727362A4 (en) 2017-12-19 2021-10-06 PureTech LYT, Inc. MYCOPHENOLIC ACID LIPID PRODRUGS AND THEIR USES
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
CA3117983A1 (en) 2018-11-15 2020-05-22 Abbvie Inc. Pharmaceutical formulations for subcutaneous administration
US11389409B2 (en) 2019-08-30 2022-07-19 Remedy Diagnostics LLC Transdermal device comprising acetaminophen prodrug
WO2021159021A1 (en) 2020-02-05 2021-08-12 Puretech Lyt, Inc. Lipid prodrugs of neurosteroids

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2444043A1 (fr) * 1978-12-15 1980-07-11 Bottu Nouveau derive du paracetamol, son procede de preparation et son utilisation en therapeutique
DK406686D0 (da) * 1986-08-26 1986-08-26 Hans Bundgaard Carboxylsyrederivater
US5001115A (en) * 1989-05-17 1991-03-19 University Of Florida Prodrugs of biologically active hydroxyaromatic compounds
JPH06501448A (ja) * 1989-12-26 1994-02-17 ノバ　ファーマシューティカル　コーポレイション 無水物プロドラッグ組成物
US5627165A (en) * 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
US5272171A (en) * 1992-02-13 1993-12-21 Bristol-Myers Squibb Company Phosphonooxy and carbonate derivatives of taxol
US6750216B2 (en) * 1996-03-08 2004-06-15 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
IT1282736B1 (it) * 1996-05-21 1998-03-31 Angelini Ricerche Spa Uso di derivati del p-amminofenolo per preparare composizioni farmaceutiche utili nel trattamento di malattie neurodegenerative
WO1998051692A1 (en) * 1997-05-15 1998-11-19 Drug Innovation & Design, Inc. Acyclovir diester derivatives
ATE261730T1 (de) * 1997-12-31 2004-04-15 Univ Kansas Wasserlösliche medikamentenvorstufen tertiärer amine enthaltender medikamente und verfahren zu ihrer herstellung
JP2002501926A (ja) * 1998-01-29 2002-01-22 ブリストル−マイヤーズ スクイブ カンパニー ジアリール１、３、４−オキサジアゾロンのホスフェート誘導体
US6204257B1 (en) * 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
TR200100708T2 (tr) * 1998-09-10 2001-07-23 Nycomed Danmark A/S İlaç maddelerine mahsus çabuk salımlı farmasötik bileşimler.
US8231899B2 (en) * 1998-09-10 2012-07-31 Nycomed Danmark Aps Quick release pharmaceutical compositions of drug substances
US6461631B1 (en) * 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
US6362172B2 (en) * 2000-01-20 2002-03-26 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
CN1213049C (zh) * 2000-03-29 2005-08-03 奥坦纳医药公司 烷基化的咪唑并吡啶衍生物及含有它们的药物和用途
IL158882A0 (en) * 2001-06-05 2004-05-12 Control Delivery Sys Inc Sustained-release analgesic compounds
WO2003065991A2 (en) * 2002-02-05 2003-08-14 Bristol-Myers Squibb Company N-substituted3-hydroxy-4-pyridinones and pharmaceuticals containing thereof
US20040058946A1 (en) * 2002-07-05 2004-03-25 Buchwald Stephen L. Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
CA2506080A1 (en) * 2002-11-14 2004-05-27 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
WO2004078180A2 (en) * 2003-03-03 2004-09-16 Guilford Pharmaceuticals Inc. Naaladase inhibitors for treating opioid tolerance
DE602004024963D1 (de) * 2003-03-13 2010-02-25 Controlled Chemicals Inc Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer
AU2003901813A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Pharmaceutical derivatives
US20050080260A1 (en) * 2003-04-22 2005-04-14 Mills Randell L. Preparation of prodrugs for selective drug delivery
US6992090B2 (en) * 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
US20050026879A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20070093457A1 (en) * 2004-02-11 2007-04-26 Nadir Arber Compositions for treatment of cancer and inflammation with curcumin and at least one nsaid
NZ590128A (en) 2004-07-06 2012-08-31 Abbott Lab Prodrugs of HIV protease inhibitors
KR20090086627A (ko) * 2006-12-05 2009-08-13 노이로제스엑스, 인코포레이티드 프로드러그 및 그것의 제조 및 사용 방법
US20110263545A1 (en) 2008-05-20 2011-10-27 Naweed Muhammad Hepatoprotectant acetaminophen mutual prodrugs
MX2010012648A (es) 2008-05-20 2010-12-14 Neurogesx Inc Analogos de acetaminofeno solubles en agua.
JP5519645B2 (ja) * 2008-05-20 2014-06-11 ニューロジェシックス， インコーポレイテッド カーボネートプロドラッグおよびそれを使用する方法
WO2010030781A2 (en) 2008-09-10 2010-03-18 Numed International, Inc. Aromatic carboxylic acid derivatives for treatment and prophylaxis of gastrointestinal diseases including colon cancer
US8575217B2 (en) 2009-03-16 2013-11-05 Genmedica Therapeutics Sl Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
US9024055B2 (en) 2011-09-22 2015-05-05 Acorda Therapeutics, Inc. Acetaminophen conjugates, compositions and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2011520977A5 (enExample)
RU2010151952A (ru) Водорастворимые аналоги ацетаминофена
RU2356547C2 (ru) Способы лечения рака с использованием ингибиторов hdac
JP2011523645A5 (enExample)
CN1468111A (zh) 治疗急性、慢性疼痛和/或神经病性疼痛和偏头痛的药物组合物
AR075735A1 (es) Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
RU2010151951A (ru) Общие пролекарства гепатопротектора и ацетаминофена
JP2012533565A5 (enExample)
WO2009067543A2 (en) Treatment of histone deacetylase mediated disorders
JP2013541583A5 (enExample)
JP7596323B2 (ja) ダクチノマイシン組成物並びに骨髄異形成症候群及び急性骨髄性白血病の治療方法
JP2019511529A5 (enExample)
MX2013013014A (es) Metodo para el tratamiento de tumores solidos avanzados.
JP2015229675A (ja) 膵臓癌を治療するための医薬製剤
ES2649492T3 (es) (S)-pirlindol o sus sales farmacéuticamente aceptables para uso en medicina
AR078170A1 (es) Metodos para el tratamiento de tumores cerebrales
RU2005133665A (ru) Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств
JP2014530204A5 (enExample)
EP3491007A1 (en) Radiolabeled ligands for targeted pet/spect imaging and methods of their use
CN102341393A (zh) 制备(+)-1，4-二氢-7-[(3s，4s)-3-甲氧基-4-甲氨基-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1，8-萘啶-3-羧酸的方法
ES2983998T3 (es) Compuesto de indol para tratar la cistitis intersticial
JP2018530612A5 (enExample)
RU2015117483A (ru) Комбинации
ES2649491T3 (es) (R)-pirlindol y sus sales farmacéuticamente aceptables para uso en medicina
RU2013148627A (ru) Производные тиено [2, 3-d] пиримидина и их применение для лечения аритмии